Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic effect of Hydroxychloroquine on IgA Nephropathy course (QUIgAN Study)
2024-512653-25-00Phase 3Authorised
- Sponsor
- CHU Saint-Etienne
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Hydroxychloroquine (Plaquenil) arm with Placebo Plaquenil arm (2 arms). Primary endpoint: Primary endpoint: GFR slope from inclusion to 3 years. Planned start Sep 2024; status: authorised.
02
Drugs
hydroxychloroquine
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2024-512653-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512653-25-00.